- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415203
TAES for FPVCs: a Pragmatic, Randomized Controlled Trial
Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Frequent Premature Ventricular Complexes: A Randomized Controlled Trial
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jiani Wu
- Phone Number: +8613426116653
- Email: jiani_wu@aliyun.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Recruiting
- Guang'anmen Hospita, China Academy of Chinese Medical Sciences
-
Contact:
- Jiani Wu
- Phone Number: +8613426116653
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed as frequent premature ventricular contractions;
- 2 ≤ Lown level ≤ 4A;
- 18 ≤ age ≤ 75;
- Volunteered to participant
Exclusion Criteria:
- Severe valvular disease, congenital heart disease, pericardial disease, hypertrophic cardiomyopathy, unstable angina pectoris, acute myocardial infarction, myocarditis, aneurysm, congestive heart failure decompensation period (NYHA grade III or VI), cardiogenic shock, cerebrovascular disease, hematopoietic system disease, severe mental disease;
- Bradycardia, including pathologic sinus node syndrome, degree II or greater atrioventricular block;
- Those who have already had pacemaker or percutaneous coronary intervention, or who plan to have pacemaker or percutaneous coronary intervention;
- Pregnant or lactating women;
- Local sensory deficit, or allergic to current;
- May be allergic to percutaneous patches;
- Blood pressure ≤ 90/60 mmHg;
- Those who have participated in other clinical trials within 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAVNS plus usual care
TAVNS on Erzhong and Xin (Auricular Acupuncture Point with Vagus nerve distribution); Usual Care: usual medicine treatment for PVCs.
|
Patients in TAVNS group will receive TAVNS and usual care.
TAVNS will be performed on Erzhong and Xin (Auricular Acupuncture Point with vagus nerve distribution) for 6 weeks by using the Huato type SDZ-V stimulator; Usual Care: usual medicine treatment for PVCs.
|
Placebo Comparator: Sham-TAVNS plus usual care
Sham-TAVNS on Erzhong and Xin (Auricular Acupuncture Point); the same acupoints as the treatment group without any current. Usual Care: usual medicine treatment for PVCs. |
Patients in sham-TAVNS group will receive sham-TAVNS and usual care.
Sham-TAVNS will be also performed on Erzhong and Xin (Auricular Acupuncture Point with vegas nerve stimulation) for 6 weeks by using a special Huato type SDZ-V stimulator.
We cut the inner electric wire of the stimulator; therefore, there is no current output.
Usual Care: usual medicine treatment for PVCs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of participants with a 50% decrease of PVCs from baseline
Time Frame: week 6
|
The PVCs will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the decrease of PVCs between baseline and week 6 (at the end of the treatment), then we will obtain the proportion of patients with a 50% decrease.
|
week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the proportion of participants with a 50% decrease of PVCs from baseline
Time Frame: week 18
|
The PVCs will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the decrease of PVCs between baseline and week 18 (at the end of the follow-up period), then we will obtain the proportion of patients with a 50% decrease.
|
week 18
|
the proportion of participants with a 75% decrease of PVCs from baseline
Time Frame: week 6, week 18
|
The PVCs will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the decrease of PVCs between baseline and week 6/18, then we will obtain the proportion of patients with a 75% decrease.
|
week 6, week 18
|
the change from baseline in PVCs
Time Frame: week 6, week 18
|
The PVCs will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the decrease of PVCs between baseline and week 6/18.
|
week 6, week 18
|
the change from baseline in total cardiac impulse
Time Frame: week 6, week 18
|
The total cardiac impulse will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the change of total cardiac impulse between baseline and week 6/18.
|
week 6, week 18
|
the change from baseline in supraventricular premature contractions
Time Frame: week 6, week 18
|
The change from baseline in supraventricular premature contractions will be assessed by a 24-hour Holter monitoring.
The investigators will calculate the change of supraventricular premature contractions between baseline and week 6/18.
|
week 6, week 18
|
the score change from baseline in the symptom of palpitation
Time Frame: week 6, week 18.
|
The symptom of palpitation will be assessed by a 10-scale VAS from 0 to 10, a higher score indicates a more severe symptom of palpitation.
The investigators will calculate the score change of palpitation between baseline and week 6/18.
|
week 6, week 18.
|
the score change from baseline in the symptom of chest tightness
Time Frame: week 6, week 18.
|
The symptom of chest tightness will be assessed by a 10-scale VAS from 0 to 10, a higher score indicates a more severe symptom of chest tightness.
The investigators will calculate the score change of chest tightness between baseline and week 6/18.
|
week 6, week 18.
|
the score change from baseline in the symptom of dizziness
Time Frame: week 6, week 18.
|
The symptom of dizziness will be assessed by a 10-scale VAS from 0 to 10, a higher score indicates a more severe symptom of dizziness.
The investigators will calculate the score change of dizziness between baseline and week 6/18.
|
week 6, week 18.
|
the score change from baseline in the symptom of insomnia
Time Frame: week 6, week 18.
|
The symptom of insomnia will be assessed by a 10-scale VAS from 0 to 10, a higher score indicates a more severe symptom of insomnia.
The investigators will calculate the score change of insomnia between baseline and week 6/18.
|
week 6, week 18.
|
the change of the proportion of participants with moderate/severe symptoms of palpitation, chest tightness, dizziness or insomnia from baseline
Time Frame: week 6, week 18.
|
The symptom of palpitation/chest tightness/dizziness/insomnia will be assessed by a 10-scale VAS from 0 to 10. Score 4-6 are defined as the moderate level, Score 7-10 are defined as the severe level.
The investigators will calculate the change of the proportion of patients with the moderate/severe symptoms between baseline and week 6/18.
|
week 6, week 18.
|
the score change from baseline in the SAS
Time Frame: week 6, week 18.
|
Self Anxiety Scale (SAS) contains 20 items scored from 25 to 100.
Score 50-59 was classified as mild anxiety; Score 60-69 as moderate anxiety, and score ≥ 70 as severe anxiety.
|
week 6, week 18.
|
the score change from baseline in the SDS
Time Frame: week 6, week 18.
|
Self Depression Scale (SDS) contains 20 items scored from 25 to 100.
Score 53-62 was classified as mild depression; Score 63-72 as moderate depression, and score ≥ 73 as severe depression.
|
week 6, week 18.
|
the score change from baseline in SF-36
Time Frame: week 6, week 18.
|
The SF-36 questionnaire contains eight scales with two measures: physical and mental health. The physical health includes four scales of physical functioning (PF), role-physical (RF), bodily pain (BP), and general health (GH). The mental health is composed of vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH). SF-36 scores from 0 to 100, higher scores indicate better health status. |
week 6, week 18.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
subgroup analysis of ages
Time Frame: week 6
|
Subgroup analysis will be performed in the primary outcome.
The investigators will classify the patients with two subgroups by age: ≤40 years and > 40 years.
|
week 6
|
subgroup analysis of gender
Time Frame: week 6
|
Subgroup analysis will be performed in the primary outcome.
The investigators will classify the patients with two subgroups by gender: male and female.
|
week 6
|
subgroup analysis of the severity of PVCs
Time Frame: week 6
|
Subgroup analysis will be performed in the primary outcome.
The investigators will classify the patients with three subgroups by the severity of PVCs through Lown: level 2, level 3, and level 4A
|
week 6
|
the proportion of participants with adverse events
Time Frame: week 6, week 18
|
Safety assessment, The investigators will calculate the adverse events during the whole study.
|
week 6, week 18
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jiani Wu, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Cardiac Complexes, Premature
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Premature Birth
- Ventricular Premature Complexes
Other Study ID Numbers
- TAESforFPVC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Ventricular Complexes
-
University of California, San FranciscoRecruitingPremature Ventricular Contraction | Premature Atrial ComplexUnited States
-
Vektor MedicalExperien GroupCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Arrythmia | Cardiac Arrhythmia | Premature Ventricular Complexes Multiple | Premature Atrial Complex | Atrioventricular Reentrant TachycardiaUnited States
-
Abbott Medical DevicesUnity Health TorontoTerminatedPremature Ventricular ComplexesCanada
-
Danderyd HospitalCompletedPremature Ventricular Contraction | Premature Ventricular Complexes MultipleSweden
-
Centre Hospitalier Universitaire VaudoisCompletedAtrial Fibrillation | Arrhythmias, Cardiac | Ventricular Tachycardia | Atrioventricular Block | Atrial Flutter | Premature Ventricular Contraction | Premature Atrial Complex | Nodal Tachycardia | Atrioventricular TachycardiaSwitzerland
-
StereotaxisCompletedVentricular Tachycardia | Premature Ventricular ContractionNetherlands, Czechia
-
Catheter Precision. Inc.Not yet recruitingVentricular Tachycardia | Ventricular Arrythmia | Premature Ventricular Contraction
-
Mayo ClinicWithdrawnVentricular Tachycardia | Premature Ventricular ContractionUnited States
-
Catheter Precision. Inc.Completed
-
University of California, San FranciscoCompletedPremature Atrial Contractions | Premature Ventricular ContractionsUnited States
Clinical Trials on Transcutaneous Auricular Vagus Nerve Stimulation (TAVNS)
-
Sahlgrenska University Hospital, SwedenRecruitingBorderline Personality DisorderSweden
-
Burrell College of Osteopathic MedicineRecruitingPsoriasis VulgarisUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedVagus Nerve Stimulation | Infant Development | Poor FeedingUnited States
-
Northwell HealthCompletedIdiopathic Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeUnited States
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingInfant Feeding Problems, taVNSUnited States
-
Burrell College of Osteopathic MedicineCompletedObesity | Diabetes Mellitus, Type 2United States
-
Medical University of South CarolinaNational Institutes of Health (NIH)Active, not recruitingStroke | Stroke Sequelae | Motor ActivityUnited States
-
University of HartfordNot yet recruitingHealthy VolunteersUnited States
-
Medical University of South CarolinaNational Institutes of Health (NIH); National Institute of General Medical...Completed
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingNeuropathic Pain | Radiotherapy Side EffectChina